HK1249515A1 - 預防和治療聽力損失的方法和組合物 - Google Patents
預防和治療聽力損失的方法和組合物Info
- Publication number
- HK1249515A1 HK1249515A1 HK18109116.0A HK18109116A HK1249515A1 HK 1249515 A1 HK1249515 A1 HK 1249515A1 HK 18109116 A HK18109116 A HK 18109116A HK 1249515 A1 HK1249515 A1 HK 1249515A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- prevention
- compositions
- treatment
- methods
- hearing loss
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562181755P | 2015-06-18 | 2015-06-18 | |
PCT/US2016/038384 WO2016205806A1 (en) | 2015-06-18 | 2016-06-20 | Methods and compositions for the prevention and treatment of hearing loss |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1249515A1 true HK1249515A1 (zh) | 2018-11-02 |
Family
ID=57546475
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18109116.0A HK1249515A1 (zh) | 2015-06-18 | 2018-07-13 | 預防和治療聽力損失的方法和組合物 |
Country Status (6)
Country | Link |
---|---|
US (3) | US20180161340A1 (zh) |
EP (2) | EP3310783B1 (zh) |
JP (2) | JP6902025B2 (zh) |
CN (1) | CN108137595B (zh) |
HK (1) | HK1249515A1 (zh) |
WO (1) | WO2016205806A1 (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108137595B (zh) | 2015-06-18 | 2021-04-20 | 听治疗有限责任公司 | 预防和治疗听力损失的方法和组合物 |
JP7291399B2 (ja) | 2017-05-03 | 2023-06-15 | ティン セラピューティクス エルエルシー | 難聴の予防および治療のための組成物および方法 |
CN108685754A (zh) * | 2018-07-30 | 2018-10-23 | 郑州兰茜生物工程有限公司 | 一种用于耳鸣及具有健耳舒耳功能的滴耳剂 |
KR102177610B1 (ko) * | 2019-03-28 | 2020-11-11 | 단국대학교 천안캠퍼스 산학협력단 | 청각세포와의 공배양을 이용한 배아줄기세포의 내이 세포로의 분화 방법 |
WO2021118924A2 (en) | 2019-12-12 | 2021-06-17 | Ting Therapeutics Llc | Compositions and methods for the prevention and treatment of hearing loss |
WO2022020114A2 (en) | 2020-07-10 | 2022-01-27 | Ting Therapeutics Llc | Methods for the prevention and treatment of hearing loss |
WO2024058527A1 (ko) * | 2022-09-13 | 2024-03-21 | 고려대학교 산학협력단 | 에스오메프라졸 또는 덱스란소프라졸을 유효성분으로 포함하는 난청 예방 또는 치료용 약학 조성물 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5910488A (en) | 1993-06-07 | 1999-06-08 | Vical Incorporated | Plasmids suitable for gene therapy |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
WO1997000957A1 (en) | 1995-06-23 | 1997-01-09 | President And Fellows Of Harvard College | Transcriptional regulation of genes encoding vascular endothelial growth factor receptors |
GB9718913D0 (en) * | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
US7132406B2 (en) | 1998-02-23 | 2006-11-07 | Sound Pharmaceuticals Incorporated | Stimulation of cellular regeneration and differentiation in the inner ear |
AU781802B2 (en) | 1999-06-01 | 2005-06-16 | Baylor College Of Medicine | Compositions and methods for the therapeutic use of an atonal-associated sequence for deafness, osteoarthritis, and abnormal cell proliferation |
FR2804959B1 (fr) | 2000-02-15 | 2006-04-28 | Centre Nat Rech Scient | Utilisation de derives de paullones pour la fabrication de medicaments |
US6548527B2 (en) * | 2000-03-27 | 2003-04-15 | The General Hospital Corporation | Treatments for immune-mediated ear disorders |
EP1278542A2 (en) | 2000-05-05 | 2003-01-29 | Cytos Biotechnology AG | Molecular antigen arrays and vaccines |
GB0025414D0 (en) | 2000-10-16 | 2000-11-29 | Consejo Superior Investigacion | Nanoparticles |
GB0205693D0 (en) * | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
US7206639B2 (en) | 2002-03-15 | 2007-04-17 | Sarcos Investments Lc | Cochlear drug delivery system and method |
US7867193B2 (en) | 2004-01-29 | 2011-01-11 | The Charles Stark Draper Laboratory, Inc. | Drug delivery apparatus |
US7612196B2 (en) | 2002-11-14 | 2009-11-03 | Dharmacon, Inc. | siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B) |
ATE409484T1 (de) * | 2002-12-17 | 2008-10-15 | Centre Nat Rech Scient | Verwendung von purinderivaten zur induktion der differenzierung überzähliger haarzellen und deiter-zellen im entwickelnden corti-organ zur behandlung von taubheit |
CN100560719C (zh) | 2003-03-26 | 2009-11-18 | 赛托斯生物技术公司 | Melan-a肽类似物-病毒样颗粒偶联物 |
GB0317127D0 (en) * | 2003-07-22 | 2003-08-27 | Astex Technology Ltd | Pharmaceutical compounds |
KR101204247B1 (ko) * | 2003-07-22 | 2012-11-22 | 아스텍스 테라퓨틱스 리미티드 | 3,4-이치환된 1h-피라졸 화합물 및 그의 시클린 의존성키나제 (cdk) 및 글리코겐 합성효소 키나제-3(gsk-3) 조정제로서 용도 |
AU2004318602B2 (en) | 2003-12-19 | 2009-12-10 | The University Of North Carolina At Chapel Hill | Methods for fabricating isolated micro- and nano- structures using soft or imprint lithography |
CA2571899A1 (en) | 2004-07-01 | 2006-08-03 | Yale University | Targeted and high density drug loaded polymeric materials |
US8404718B2 (en) * | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
US20080207594A1 (en) | 2005-05-04 | 2008-08-28 | Davelogen Aktiengesellschaft | Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders |
WO2007030743A2 (en) | 2005-09-08 | 2007-03-15 | Massachusetts Eye & Ear Infirmary | Cochlear implants containing biological cells and uses thereof |
US7754700B2 (en) * | 2006-04-24 | 2010-07-13 | Trager Seymour F | Composition and methods for alleviating symptoms of neurotoxicity |
JP2010509919A (ja) | 2006-11-15 | 2010-04-02 | マサチューセッツ・アイ・アンド・イア・インファーマリー | 内耳細胞の生成 |
WO2008124165A2 (en) | 2007-04-09 | 2008-10-16 | Chimeros, Inc. | Self-assembling nanoparticle drug delivery system |
DE102007032579B4 (de) | 2007-07-09 | 2017-05-04 | Tyco Electronics Services Gmbh | Endverschluss für die Telekommunikations- und Datentechnik |
WO2009010298A2 (en) | 2007-07-18 | 2009-01-22 | Technische Universität Carolo-Wilhelmina Zu Braunschweig | Paullone derivatives and its use |
MX350501B (es) | 2007-10-12 | 2017-09-07 | Massachusetts Inst Technology | Nanotecnologia de vacuna. |
WO2009061345A2 (en) * | 2007-11-07 | 2009-05-14 | Cornell Research Foundation, Inc. | Targeting cdk4 and cdk6 in cancer therapy |
US20090130118A1 (en) * | 2007-11-19 | 2009-05-21 | Bionovo, Inc. | Scutellaria barbata extract and combinations for the treatment of cancer |
US8004501B2 (en) | 2008-01-21 | 2011-08-23 | Sony Computer Entertainment America Llc | Hand-held device with touchscreen and digital tactile pixels |
JP2011511806A (ja) | 2008-02-07 | 2011-04-14 | マサチューセッツ・アイ・アンド・イア・インファーマリー | Atoh1発現を増強する化合物 |
US20120015899A1 (en) | 2008-10-25 | 2012-01-19 | Plant Bioscience, Limited | Modified plant virus particles and uses therefor |
US10143711B2 (en) * | 2008-11-24 | 2018-12-04 | Massachusetts Eye & Ear Infirmary | Pathways to generate hair cells |
EP2576783B1 (en) | 2010-05-26 | 2017-11-29 | CuRNA, Inc. | Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1 |
GB201107176D0 (en) * | 2011-04-28 | 2011-06-15 | Cxr Biosciences Ltd | Pyrrolnitrin derivatives |
WO2013071415A1 (en) * | 2011-11-15 | 2013-05-23 | University Health Network | Targeting the rb pathway for the prevention of cancer |
WO2014083132A1 (en) * | 2012-11-29 | 2014-06-05 | Cellectis Sa | Maturation of hepatocyte-like cells derived from human pluripotent stem cells |
US9572815B2 (en) | 2013-03-15 | 2017-02-21 | St. Jude Children's Research Hospital | Methods and compositions of p27KIP1 transcriptional modulators |
CN108137595B (zh) | 2015-06-18 | 2021-04-20 | 听治疗有限责任公司 | 预防和治疗听力损失的方法和组合物 |
-
2016
- 2016-06-20 CN CN201680046636.7A patent/CN108137595B/zh active Active
- 2016-06-20 JP JP2018517685A patent/JP6902025B2/ja active Active
- 2016-06-20 US US15/580,224 patent/US20180161340A1/en not_active Abandoned
- 2016-06-20 WO PCT/US2016/038384 patent/WO2016205806A1/en active Application Filing
- 2016-06-20 EP EP16812629.0A patent/EP3310783B1/en active Active
- 2016-06-20 EP EP20197304.7A patent/EP3786164A1/en active Pending
-
2018
- 2018-07-13 HK HK18109116.0A patent/HK1249515A1/zh unknown
-
2019
- 2019-12-09 US US16/707,991 patent/US11446308B2/en active Active
-
2020
- 2020-09-18 JP JP2020156803A patent/JP7257367B2/ja active Active
-
2022
- 2022-07-12 US US17/862,656 patent/US20230000881A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3310783A1 (en) | 2018-04-25 |
JP2018522064A (ja) | 2018-08-09 |
CN108137595A (zh) | 2018-06-08 |
JP2021001201A (ja) | 2021-01-07 |
JP7257367B2 (ja) | 2023-04-13 |
CN112933094A (zh) | 2021-06-11 |
US11446308B2 (en) | 2022-09-20 |
EP3310783B1 (en) | 2020-11-04 |
US20230000881A1 (en) | 2023-01-05 |
US20180161340A1 (en) | 2018-06-14 |
EP3786164A1 (en) | 2021-03-03 |
EP3310783A4 (en) | 2018-12-26 |
US20200179397A1 (en) | 2020-06-11 |
CN108137595B (zh) | 2021-04-20 |
WO2016205806A1 (en) | 2016-12-22 |
JP6902025B2 (ja) | 2021-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1258205A1 (zh) | 用於治療血紅蛋白病的組合物和方法 | |
EP3347469A4 (en) | METHOD AND COMPOSITIONS FOR TREATING GLAUCOMA | |
ZA201707303B (en) | Compositions and methods for the treatment of immunodeficiency | |
EP3408344A4 (en) | METHOD AND COMPOSITIONS FOR BORING TREATMENT | |
HK1249515A1 (zh) | 預防和治療聽力損失的方法和組合物 | |
ZA202104969B (en) | Compositions comprising 15-hepe and methods of using the same | |
EP3182989A4 (en) | Methods and compositions for the prevention and treatment of disease | |
ZA201902781B (en) | Compositions and methods for the treatment of xerostomia | |
HK1245657A1 (zh) | 預防或治療聽力損失的方法 | |
SG11201702554QA (en) | Compositions and methods for the treatment of multiple sclerosis | |
EP3368048A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOID DOSE | |
HK1257853A1 (zh) | 用於治療和預防放射性皮炎的組合物和方法 | |
HK1258502A1 (zh) | 用於治療高胱氨酸尿症的組合物和方法 | |
HK1247136A1 (zh) | 包含15-hepe的組合物和其使用方法 | |
EP3341006A4 (en) | COMPOSITIONS AND METHODS FOR TREATING NERVE DAMAGE | |
ZA201900984B (en) | Methods and compositions for the treatment of warts | |
HK1255695A1 (zh) | 用於治療眼瞼下垂的組合物和方法 | |
GB201511799D0 (en) | Composition and methods of treatment | |
GB201621737D0 (en) | Compositions and methods of treatment | |
EP3139744A4 (en) | Methods and compositions for treating and preventing tinnitus | |
ZA201706985B (en) | Compositions for the treatment of fibrosis and fibrosis-related conditions | |
DK3313207T3 (en) | Compositions and methods for the treatment of malnutrition | |
EP3294417A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GLIOMES | |
GB201605127D0 (en) | Composition and methods of treatment | |
EP3383369A4 (en) | Compositions and methods for ear prophylaxis and treatment |